For the millions of adults who develop chest pain after viral illness — or after mRNA vaccination — the clinical management of heart inflammation has long been inconsistent and contested. Two landmark guideline documents from the world's leading cardiology bodies now offer a substantially updated, more unified framework that could meaningfully change how clinicians identify and treat myocarditis and pericarditis.
The 2025 European Society of Cardiology (ESC) guidelines and the 2024–2025 American College of Cardiology (ACC) consensus documents share a critical diagnostic pivot: cardiac magnetic resonance imaging (CMR) is now positioned to frequently replace immediate endomyocardial biopsy in stable, uncomplicated acute myocarditis cases. The ESC introduces an overarching conceptual framework called "inflammatory myopericardial syndrome" (IMPS), designed to capture myocarditis, pericarditis, and their overlap presentations under a single diagnostic umbrella. The ACC, by contrast, preserves separate diagnostic pathways while adding a novel four-stage clinical classification specific to myocarditis. On the therapeutic front, both bodies endorse NSAIDs and colchicine for pericarditis management, while reserving immunosuppression for carefully selected patients. Most notably, interleukin-1 (IL-1) receptor blockade — exemplified by agents such as anakinra — earns a Class I recommendation from the ESC for recurrent pericarditis, with strong parallel endorsement from the ACC.
This dual-guideline convergence carries real analytical weight. The IL-1 pathway designation as first-line therapy for recurrent disease represents a genuine mechanistic shift: it moves inflammatory cardiac disease management from broad anti-inflammatory suppression toward targeted cytokine modulation — a trajectory already transforming rheumatology and autoinflammatory disease management. The CMR-first approach also reflects accumulating evidence that tissue characterization via T1/T2 mapping offers diagnostic sensitivity once attributed only to biopsy. Clinicians and health-aware adults should note, however, that this Italian cardiology working group appraisal is a position paper, not a primary clinical trial — it synthesizes expert interpretation of guidelines rather than new outcome data. Harmonization gaps in terminology and diagnostic thresholds between ESC and ACC systems remain, and real-world applicability across diverse healthcare settings warrants scrutiny.